Study on the Safety and Effectiveness of GSK5926371 for Adults with Returning or Resistant B-Cell Blood Cancer

Inclusion Criteria

• Diagnosed with B-cell Non-Hodgkin Lymphoma that has returned or not responded to treatment, and needs systemic treatment.
• Have measurable cancer that can be tracked.
• Have received at least two previous treatments, including one that targets CD20, which is appropriate for this type of cancer.
• The cancer must have returned, progressed, or not responded to the most recent treatment, according to specific medical criteria.
• Willing to use effective birth control if of childbearing potential.
• Able to provide informed consent to participate in the study.
• Have a performance status score between 0 and 2, indicating full activity or some restriction in strenuous activities.
• Have adequate organ function as determined by medical tests.

Exclusion Criteria

• Have another type of cancer that has progressed or needed treatment in the past 24 months, except for certain skin cancers or in-situ cancers that have been removed.
• Have had major surgery within the past 4 weeks or have not fully recovered from surgery.
• Have a history of certain brain diseases or conditions, such as uncontrolled seizures or stroke.
• Have an active, uncontrolled infection.
• Have had an allogeneic stem cell transplant within the past 12 months or have active graft-versus-host disease.
• Have had an autologous stem cell transplant within the past 100 days.
• Have received CAR-T therapy within the past 12 weeks.
• Have received treatment with certain antibodies targeting CD19 or CD20 within the past 8 weeks.
• Have a prolonged QT interval on an ECG, which is a measure of heart rhythm.
• Have significant heart disease, such as uncontrolled arrhythmias or recent heart attack.